|
Safety Data Sheet
<br />Material Name: Copper Sulfate Pentahydrate ID: C l-121A
<br />* * * Section 11 -Toxicological Information Continued * * *
<br />B: Component Analysis-TDLo!LDLo
<br />Copper S u l fate Penta hydrate (7758-99-8)
<br />Oral-man LDLo: 857 mg/kg; Oral-lfuman LDLo ; 50 mg/kg: Behavioral: somnolence (general depressed activity); Kidney, Urethra,
<br />Bladder: c hanges in tubules (including acute rena l failu re, acu te tubular necrosis): B lood: hemorrhage; Oral-Human TDLo: 11 mg/kg:
<br />Gastrointestin al : gastritis; Gastrointestinal: hypermoti lity, diarrhea, nausea or vomiting; Oral-Human TDLo: 272 mg/kg: livor. kldney,
<br />Blood effects; Ora l-Human LDLo: I 088 mg/kg; Oral-child : ISO mg/kg: Kidney, Urethra, Bladder: changes in tubules (incl uding acute
<br />renal failure, acu te tubular; necrosis); Blood: other hemolysis with or without anemia; unknown-Man LDLo : 221 mg/kg; Oral-Woman
<br />TDLo: 2400 mg/kg/day: Gastrointestinal tTact effects; DNA lnhlbition-Human: lymphocyte 76 mmoi/L; Oral -woman LDLo: 100 mg/kg:
<br />Vascu lar: Blood press ure lowering not characterized in autonomic section; Liver: hepatitis (hepatocellular necrosis), d iffuse; Kidney,
<br />Urethra, Bladder: c han ges in tubules (including acute renal fai lure, acute tubular necrosis); Oral-Human LDLo: 143 mg/kg: Pulmonary
<br />system effects, Gastrointestinal tract effects ;Oral-rat TDLo: 915 mg/kg/1 year-intermittent: Cardiac: changes in coronary arteries; Blood :
<br />c hanges in seru m composition (e.g. TP, bilirub in , cholesterol; Oral -rat TDLo: J 57 mg/kg/6 weeks-interm itte nt: E ndocri ne: changes in
<br />adrenal weight; Nutritional and G ross Metabolic: weight loss or decreased we ight gain; Biochemica l: Enzyme inhibition, induction , or
<br />change in blood or tissue level.s : dehydrogenases; Oral-rat TDLo: 7530 mg/k:g/30 days-intermittent: Bl ood : c hanges in serum composition
<br />(e.g. TP, bilirubin. cholesterol); B lood: changes in erythrocyte (RBC) count; Biochemical: Enzyme inhibition, induction, or change in
<br />b lood o r tissue levels:-multiple enzyme effect; Oral-rat TDLo: 2 gm/kg/20 days-intermittent: Liver: other changes; Biochemical: Enzyme
<br />inhibition, induction. or change in blood or ti ssue levels: phosphatases, E nzyme inhibition, induction , or change in blood or tissue levels;
<br />Intraperitoneal-rat TDLo: 791 mg/kg/18 weeks-intermi ttent: Nutritional anc.l Gross Metabolic: weight loss or decreased weight gain;
<br />lnt1·apetitoneal-rat TDLo: 7500 !J g/kg: fema le 3 day(s) after conception: Reproductive: Fertility: other measures of fertili ty;
<br />Subcutaneousrat TDLo: 12768 ).Jg/kg: male I day(s) pre-mating: Reproductive: Paternal Eftects: testes, epididymis, sperm duct;
<br />lnlTatesticular-rat TDLo:3 192 !J g/kg: male I day(s) pi·e-mating: Reproducti ve: Paternal Effects: spetmatogenesis (in cl. genetic material,
<br />sperm morphology, motility, and count), t estes, epididymis, sperm duct; Oral-mouse TDLo: 3 gm/kg/8 weeks-cont inu ous: Blood: changes
<br />in spleen; Immlmol ogica l Lnclud ing Allergic: decrease i.n cellular immune response, decrease in humoral immune response; Oral-mouse
<br />TDLo: 2 gm/kg/3 weeksconti nu ous:
<br />B lood: changes in spleen; fmmunologicallncluding Allergic: decrease in cellu lar im mune response, decrease in humoral
<br />immune response; Subcutaneo us-mouse LDLo: 500 !J g/kg; S ub cutaneous-mouse TDLo: 12768 !J g/kg: male 30 day(s) pre-mating:
<br />Reproductive: Paternal Effects: testes, epid id ymis, sperm duct; Intravenous -mouse TDLo: 3200 !J g/kg: female 8 day(s) atier conception:
<br />Reproductive: Effects on Embryo or Fetus: fetotoxicity (except death, e .g., stunted fe tu s), Specific Developmental Abno rm a l ities: Central
<br />Nervous Syste m, cardiovascular (circulatory) system; Intravenous-mouse TDLo: 3200 ).J g/kg: female 7 day(s) after conception:
<br />Reproductive: Ferti lity: post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants); Oral-Dog, adult
<br />LDLo : 60 mg/kg; Intrave nous-guinea pig TDLo: 2 mg/kg; Subcutaneous-Guinea Pig, adult LDLo: 62 mg/kg ; Oral-Pigeon LDLo: I 000
<br />mg/kg ; Oral-Domestic anima ls (Goal, S heep) LDLo: 5 mglkg; Oral-Bird-wild spec ies LDLo: 300 mg/kg; Intravenous-frog LDLo: 25
<br />mg/kg; Parenteral-chicken TDLo: 10 mg/kg: T umorigenic: equivocal tum origenic agent by RTECS criteria; Endocrine : tumors; Oral-pig
<br />TDLo: 140 mg/kg: female l-1 S weekts) after co nc eption, lactating fe male 4 week(s) post-bitih: Reproductive: Effects on Newborn:
<br />biochemical and metabo lic; Intravenous-hamster TDLo: 2130 !Jg/kg: fe male 8 day(s) after conception: Reproductive: Fetiility:
<br />post imp lantationmortality (e.g. dead and /or resorbed implants per total number of imp lants), Specifi c Developmental J\bnonnalit ies:
<br />Central Nervous System, body wall
<br />Carcin ogenicity
<br />A: General Product Informat ion
<br />Copper S ulfate Pcntahydrate (7758-99-8)
<br />Cytogenetic Analysis-Rat/ast 300 mg/kg
<br />B: Component Carcinogenici ty
<br />C opper dusts and mists, as Cu (7440-50-8)
<br />EPA: EPA-D (Not Classifiable as to Human Carcinogenicity -inadequate human and anima l ev id e nce of carcin ogeni city
<br />or no data available)
<br />Epidemiology
<br />No informat ion avai lable.
<br />Ne uro toxi c ity
<br />Has not been id entified.
<br />Issue Date: 09/09/98 13:25:58 CLW Page/ ofl4 .Revision Date: 01 /14/2015 J 3:00 CST
<br />6.3.A. - Page 142
|